MY170949A - A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine - Google Patents

A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine

Info

Publication number
MY170949A
MY170949A MYPI2011003259A MYPI2011003259A MY170949A MY 170949 A MY170949 A MY 170949A MY PI2011003259 A MYPI2011003259 A MY PI2011003259A MY PI2011003259 A MYPI2011003259 A MY PI2011003259A MY 170949 A MY170949 A MY 170949A
Authority
MY
Malaysia
Prior art keywords
peptide
cancer vaccine
hla
binding
molecule
Prior art date
Application number
MYPI2011003259A
Inventor
Sok Ching Cheong
Soo Hwang Teo
Kue Peng Lim
Mohd Zain Rosnah
Ariff Abdul Rahman Zainal
Ponniah Sathibalan
Original Assignee
Cancer Res Initiatives Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Initiatives Foundation filed Critical Cancer Res Initiatives Foundation
Priority to MYPI2011003259A priority Critical patent/MY170949A/en
Priority to PCT/MY2012/000198 priority patent/WO2013009165A1/en
Priority to TW101124710A priority patent/TWI567088B/en
Publication of MY170949A publication Critical patent/MY170949A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a peptide comprising at least an amino acid sequence selected from at least a portion of MAGE-D4b protein, which the peptide is capable of binding with at least a human leukocyte antigen (HLA) molecule. The binding of the peptide with the human leukocyte antigen (HLA) molecule described herein, is capable of inducing the immune system of a subject to recognize oral cancer cells as being foreign. Upon being recognized as foreign particles, these cells are targeted and destroyed by the CD8+ cytotoxic T cells. Further disclosed in the present invention is a cancer vaccine derived from the MAGE-D4b peptides and the use of said cancer vaccine. Most illustrative drawing: Figure 1
MYPI2011003259A 2011-07-11 2011-07-11 A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine MY170949A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
MYPI2011003259A MY170949A (en) 2011-07-11 2011-07-11 A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine
PCT/MY2012/000198 WO2013009165A1 (en) 2011-07-11 2012-07-05 A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine
TW101124710A TWI567088B (en) 2011-07-11 2012-07-10 Peptide capable of binding with a human leukocyte antigen (hla) molecule, cancer vaccine derived from said peptide, and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI2011003259A MY170949A (en) 2011-07-11 2011-07-11 A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine

Publications (1)

Publication Number Publication Date
MY170949A true MY170949A (en) 2019-09-20

Family

ID=47506273

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2011003259A MY170949A (en) 2011-07-11 2011-07-11 A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine

Country Status (3)

Country Link
MY (1) MY170949A (en)
TW (1) TWI567088B (en)
WO (1) WO2013009165A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY192920A (en) * 2017-03-15 2022-09-15 Cancer Res Malaysia Immunogenic peptide composition
US11497768B2 (en) * 2017-06-05 2022-11-15 Mie University Antigen-binding protein that recognizes MAGE-A4-derived peptide
CN114959031A (en) * 2022-05-20 2022-08-30 上海交通大学医学院附属瑞金医院 Marker combination for pancreatic adenocarcinoma prognosis evaluation and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004026135A1 (en) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh Tumor-associated peptides binding to MHC molecules
PL1760089T3 (en) * 2005-09-05 2010-03-31 Immatics Biotechnologies Gmbh Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
EP2334826A4 (en) * 2008-09-12 2012-01-25 Cancer Res Initiative Foundation METHOD FOR DETECTION AND DIAGNOSIS OF ORAL AND RHINO-PHARYNGIAN CANCERS

Also Published As

Publication number Publication date
TWI567088B (en) 2017-01-21
TW201302801A (en) 2013-01-16
WO2013009165A1 (en) 2013-01-17

Similar Documents

Publication Publication Date Title
MX355074B (en) Diagnosis and treatment of cancer based on avl9.
UA103751C2 (en) Immunogenic peptide for immunotherapy
NZ733168A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
CY1123526T1 (en) INNOVATIVE IMMUNOTHERAPY AGAINST VARIOUS TUMORS INCLUDING NEURON AND BRAIN TUMORS
BR112016009402A2 (en) PEPTIDE, ACTIVATED CYTOTOXIC T-LYMPHOCYTES (CTL), METHOD FOR THEIR PRODUCTION, ANTIBODY, T-CELL RECEPTOR, NUCLEIC ACID, HOST CELL, USE THEREOF, KIT, METHOD FOR PRODUCING A CUSTOMIZED ANTI-CANCER VACCINE FOR AN INDIVIDUAL PATIENT
PE20240645A1 (en) IMMUNOGENIC PEPTIDE DERIVED FROM HUMAN LEUKOCYTE ANTIGEN (HLA) MOLECULES AS A BIOMARKER IN THE IMMUNOTHERAPY OF VARIOUS TUMORS
EA201791925A1 (en) NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR THE APPLICATION IN IMMUNOTHERAPY OF SEVERAL TUMOR SPECIES
WO2012027379A3 (en) Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
NZ712148A (en) Wt1 antigen peptide conjugate vaccine
DK2280721T3 (en) Indoleamin-2,3-dioxygenase-based immunotherapy
EP2228072A4 (en) VACCINE COMPOSITION AGAINST CANCER
MX2014004214A (en) Recombinant self-replicating polycistronic rna molecules.
EA201071297A1 (en) NEW AND EFFECTIVE PEPTIDES OF THE MHC II CLASS RECEIVED FROM Survivin
JP2014502961A5 (en)
NZ594198A (en) Neil3 peptides and vaccines including the same
EP2528937A4 (en) MODIFIED MELK PEPTIDES AND ASSOCIATED VACCINES
MY170949A (en) A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
UA113413C2 (en) MPHOSPH1 Peptide And Vaccine That Contains It
MX369413B (en) Peptide.
NZ611361A (en) Tomm34 peptides and vaccines including the same
MX2013004417A (en) Wdhd1 peptides and vaccines including the same.
SG10201408245WA (en) Tmem22 peptides and vaccines including the same
BR112013009276A2 (en) c18orf54 peptides and vaccines including the same
NZ593086A (en) Isolated peptide binding to human leukocyte antigen (HLA) and having cytotoxic T lymphocyte (CTL) inducibility